Last reviewed · How we verify
Octreoscan (PENTETREOTIDE)
At a glance
| Generic name | PENTETREOTIDE |
|---|---|
| Sponsor | Sun Pharm Inds Inc |
| Modality | Recombinant protein |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2024 |
Approved indications
- primary neuroendocrine tumors
- metastatic neuroendocrine tumors
Common side effects
- Nausea
- Injection site pain
- Diarrhea
- Abdominal pain/discomfort
- Loose stools
- Vomiting
- Hypertension
- Hyper- and hypoglycemia
- Hypersensitivity reactions
- Rash
- Pruritus
- Angioedema
Key clinical trials
- 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs) (NA)
- Asymptomatic Small Pancreatic Endocrine Neoplasms.
- Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors (PHASE2,PHASE3)
- Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT (PHASE2)
- Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors (PHASE1,PHASE2)
- New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome (PHASE2)
- Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis (NA)
- Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Octreoscan CI brief — competitive landscape report
- Octreoscan updates RSS · CI watch RSS
- Sun Pharm Inds Inc portfolio CI